DNS Capital
VC Fund
Chicago, United States
DNS Capital is an investment office for the business enterprise of Gigi Pritzker, Michael Pucker, and their immediate family that provides long-term control and minority investments in companies.DNS Capital takes a long-term and flexible approach to invest by building relationships with business owners, management teams, and entrepreneurs toalign interests, evolve businesses, and create lasting value with a sense of purpose and a sense of humor.
- Total investments:
- 56
- Last investment:
- Lead investor:
- 25%
Last updated:
For AI agents: llms.txt
Industries DNS Capital invests in
Stages DNS Capital invests in
Countries DNS Capital invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Andrew Dzwonchyk
|
|||
Michael Pucker
|
|||
Elizabeth Hess
|
|||
Emily Casey
|
|||
Gigi Pritzker
|
|||
| See all 6 contacts → | |||
Investment Focus
Industry
- Software 8 (14%)
- Artificial Intelligence 7 (13%)
- FinTech 5 (9%)
- Health Care 5 (9%)
- Biotechnology 5 (9%)
Stage
- Series A 11 (20%)
- Series B 10 (18%)
- Series C 8 (14%)
- Series D 6 (11%)
- Funding Round 5 (9%)
Country
- United States 29 (52%)
- Spain 1 (2%)
- Canada 1 (2%)
- Sweden 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Andrew Dzwonchyk
Principal
|
Principal | Total investments: 1 | Find email | |
|
Michael Pucker
CEO
|
CEO | Total investments: 4 | Find email | |
|
Elizabeth Hess
Head of Business Development
|
Head of Business Development | Total investments: 0 | Find email | |
|
Emily Casey
Vice President
|
Vice President | Total investments: 4 | Find email | |
|
Gigi Pritzker
Co-Founder
|
Co-Founder | Total investments: 2 | Find email | |
| See all 6 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Seasats
|
Seasats autonomous ocean vehicles provide remote monitoring and data collection for defense and commercial customers at a fraction of the cost, logistics, and risk compared to traditional methods. | $20M / Series A / Feb 17, 2026 | |
Tensordyne
|
Recogni was incorporated in 2017 to help auto manufacturers reach Level 2+ vehicle autonomy, but their roots go way back to 2013. The company's platform delivers unprecedented inference performance and power efficiency, enabling clients to get novel edge processing | $35M / Series C / Jul 28, 2025 | |
Vermillio
|
Vermillio is an AI platform that allows content creators to style, own, and tracks their digital creations. The company's tools generate content that is authenticated using its proprietary blockchain technology which determines ownership. Vermillio was founded by Dan Neely and is based in Chicago, Illinois. | $16M / Series A / Mar 03, 2025 | |
Quantifind
|
Quantifind provides AI solutions for anti-money laundering and fraud detection that uniquely discover risk by combining internal financial institution data with public domain data. Founded in 2008 by two atomic physics Ph.D.s, the company has offices in Silicon Valley, New York, and Washington, DC. For more information, please visithttp://www.quantifind.com. | $22M / Jan 17, 2025 | |
DaCapo Brainscience
|
DaCapo Brainscience is a biotechnology company focused on developing the first disease-modifying therapies for neurodegenerative diseases. With a mission centered on addressing the challenges of conditions such as Parkinson's disease, DaCapo Brainscience leverages deep expertise in the field to pioneer innovative treatments. The company'sapproach includes targeting the accumulation of specific proteins in the brain, which are associated with the progression of neurodegenerative diseases. DaCapo Brainscience is committed to advancing research and development to offer new paths forward for patients affected by these conditions. The team consists of professionals with extensive experience in biotechnology, working towards making significant contributions to the field of neuroscience. | $2M / Convertible Note / Nov 20, 2024 | |
Truvian Sciences
|
Truvian disrupts the blood-testing industry by developing an automated, benchtop diagnostic system to provide lab-accurate results.The blood-testing system combines chemistry, immunoassays, and hematology assays in one device. With its 20-minute, single-run wellness panel that requires only several drops of blood, the company aims to cover about40 commonly ordered diagnostic tests, including a lipid panel, metabolic panel, and complete blood cell count. Its dry reagent and optical sensing technologies, which require no refrigeration, can perform a complete blood count, basic metabolic and lipid panel, hemoglobin and glucose tests, thyroid screenings, and liver and kidney function exams. The company also offers Easy Check, a blood-based serologic test Truvian claims can detect the presence of the antibodies effective against SARS-CoV-2, the virus that causes COVID-19.Dena Marrinucci, Kim Kamdar, Mark Bowles, and Pieter van Rooyen established the San Diego, California-based company in 2015. | $74M / Jul 17, 2024 | |
|
Truvian Sciences
|
Truvian disrupts the blood-testing industry by developing an automated, benchtop diagnostic system to provide lab-accurate results.The blood-testing system combines chemistry, immunoassays, and hematology assays in one device. With its 20-minute, single-run wellness panel that requires only several drops of blood, the company aims to cover about40 commonly ordered diagnostic tests, including a lipid panel, metabolic panel, and complete blood cell count. Its dry reagent and optical sensing technologies, which require no refrigeration, can perform a complete blood count, basic metabolic and lipid panel, hemoglobin and glucose tests, thyroid screenings, and liver and kidney function exams. The company also offers Easy Check, a blood-based serologic test Truvian claims can detect the presence of the antibodies effective against SARS-CoV-2, the virus that causes COVID-19.Dena Marrinucci, Kim Kamdar, Mark Bowles, and Pieter van Rooyen established the San Diego, California-based company in 2015. | $74M / Series D / Jul 17, 2024 | |
Hero Bread
|
Hero Bread is a food product company that specializes in providing nutritious foods. The company is headquartered in San Francisco, USA. | $21M / Series B / Jun 26, 2024 | |
|
Tensordyne
|
Recogni was incorporated in 2017 to help auto manufacturers reach Level 2+ vehicle autonomy, but their roots go way back to 2013. The company's platform delivers unprecedented inference performance and power efficiency, enabling clients to get novel edge processing | $102M / Series C / Feb 20, 2024 | |
MetOx Technologies
|
MetOx is a commercial manufacturer of high-temperature superconducting (HTS) wire using YBCO. HTS wire transmits transmits vast amounts of electricity in small cross-sections without electrical loss and without generating heat. HTS wire is critical for upgrading transmission and distribution lines (T&D), enabling magnetic confinement fusionreactors, and building next generation MRI scanners. | Series B / Dec 12, 2023 | |
| See all 56 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does DNS Capital invest in?
DNS Capital invests primarily in Software, Artificial Intelligence and FinTech startups, most often at Series A and Series B stage. Most of the 56 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact DNS Capital?
Public channels for DNS Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at DNS Capital?
The team at DNS Capital includes Andrew Dzwonchyk (Principal), Michael Pucker (CEO) and Elizabeth Hess (Head of Business Development), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
